iShares Bitcoin Trust vs Medpace Holdings Inc — how do they compare? iShares Bitcoin Trust trades at $35.94, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| IBIT | MEDP | |
|---|---|---|
Sector | Crypto-linked | Technology |
52-Week High | $71.29 | $620.59 |
52-Week Low | $33.29 | $393.42 |
Market Cap | — | $16.90B |
Enterprise Value | — | $16.52B |
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $35.89, down 0.94% with bearish technical signals from moving averages. The stock faces selling pressure but shows neutral oscillator readings. Recent news highlights institutional interest with Alpha Zero LLC increasing its position by 43.8% in Q1 2026 (SEC filing, 2026-07-21). Bitcoin ETF flows show selective demand, with IBIT leading recent inflows after seven straight days of buying (ETF Trends, 2026-07-23).
The outlook remains cautious due to technical bearishness and Bitcoin's 44% decline from 2025 peaks. Long-term potential exists from institutional adoption, but investors face volatility risks. Analyst sentiment is mixed, with some recommending accumulation for long-term holders while technical indicators suggest near-term pressure.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →